Unlike every other Big Pharma company in the world, Novartis tends to prefer to communicate rather selectively when it chops a facility here or winnows out its ranks over there in its global structure.
AstraZeneca is cutting an additional 550 jobs from its ranks, bringing the total to 5,600 in an expanded restructuring designed, in part, to give it more money for deals.
Novartis apparently has job cuts on its January to-do list. After announcing a 500-job shuffle in Switzerland yesterday, the drugmaker now confirms that it will shutter a New York plant that employs 525 people.
Merck early in December agreed to sell the rights to its antipsychotic drug Saphris to Forest Laboratories for $240 million. The move not only gave it a small cash boost, but it turns out it also will help it put another 150 jobs on the restructuring pyre as it looks to shed 8,500 workers and $2.5 billion in costs.
The regenerative medicine company Organogenesis is slashing jobs as part of its company-wide reorganization in the face of Medicare's decision to cut what it's paying for its wound-healing medicine Apligraf.
Workers at the plant in Mississauga, Ontario, got the news that layoffs will begin in May and operations will wind down by the end of next year.
The past few weeks have seen a spate of pharma manufacturing cuts, with Actavis, Merck and Pfizer all whacking jobs. And Pfizer has continued its busy end to 2013 by revealing it is to close a packaging plant in Ireland, laying off 150 workers in the process.
Eisai announced late last week that it is bringing the ax down on its R&D facility in Andover, MA, and other research centers around the globe as it chops 130 staffers out of its operations.
In the latest round of layoffs, Dendron plans to save $125 million in operating expenses by cutting its headcount by 15%. Around 150 full-time employees are set to lose their jobs over the next nine months as Dendreon cuts its R&D and marketing budgets in a bid to achieve profitability.
Shire is prepping a plan to cut back on its sizable research operations in Basingstoke, U.K.--another setback for the country's research industry with Novartis axing more than 500 staffers and consultants in Horsham following major blows from AstraZeneca and Pfizer.